FHTX
Companies
NASDAQ
Foghorn Therapeutics Inc.
Health Care
$4.72
$0.00 (0.00%)
Price Chart
Overview
About FHTX
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Market Cap
$332.5M
Volume
685.4K
Avg. Volume
567.1K
P/E Ratio
-2.2246835
Dividend Yield
0.00%
Employees
141.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.20
Moderate Correlation
Volatility
High (0.92)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
High Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, FHTX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$332.5M
Volume685.4K
P/E Ratio-2.22
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 7, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025